FDA Authorizes First Wearable Device That Monitors Ketone And Blood Sugar Levels

The U.S. Food and Drug Administration (FDA) has approved the first wearable device capable of continuously monitoring both ketone and blood sugar levels. This device, developed by a medical technology company, aims to provide real-time data to individuals with diabetes, potentially improving disease management and early detection of diabetic ketoacidosis (DKA). The approval marks a significant milestone in wearable health technology, offering a new tool for personalized, proactive care.

The device, named KetoneSense, is designed as a wrist-worn sensor that uses advanced biosensing technology to measure ketone and glucose levels through the skin. The FDA’s authorization follows clinical trials that demonstrated its accuracy and safety, with the device providing continuous data streams to a paired mobile app. Users can receive alerts if their ketone or blood sugar levels reach concerning thresholds, enabling timely intervention.

According to the manufacturer, KetoneSense is intended for use by adults with diabetes, particularly those at risk of ketoacidosis, a serious complication caused by high ketone levels. The device is not yet approved for pediatric use, and its long-term efficacy and impact on health outcomes are still being studied. The FDA emphasized that the device is intended to support, not replace, standard blood testing and medical advice.

Impact of Dual Monitoring on Diabetes Management

This approval introduces a new level of monitoring that could significantly enhance how individuals with diabetes manage their condition. By providing real-time data on both ketone and blood sugar levels, the device may enable earlier detection of dangerous shifts, such as ketoacidosis, potentially reducing hospitalizations and improving quality of life. Healthcare professionals see this as a step toward more personalized, data-driven care, though it remains to be seen how widely the device will be adopted and integrated into existing treatment plans.

Previous Advances and the Need for Integrated Monitoring

Prior to this approval, continuous glucose monitors (CGMs) have become standard tools for many people with diabetes, providing real-time blood sugar data. However, monitoring ketone levels typically required manual blood tests or urine strips, which are less convenient and often delayed. The development of a wearable that can track both metrics simultaneously addresses a longstanding gap in diabetes management. The FDA’s move follows increasing interest in integrated biosensors and personalized health devices, driven by technological advances and a growing emphasis on early intervention.

Major companies and startups have been exploring non-invasive sensors for ketone detection, but few have reached regulatory approval. The recent authorization underscores the potential for wearable biosensors to transform chronic disease management, especially for conditions like type 1 diabetes, where rapid changes can be life-threatening.

“This is the first device to provide continuous, real-time monitoring of both ketone and blood sugar levels, representing a significant step forward in diabetes care.”

— Dr. Lisa Chen, FDA Medical Devices Director

Long-term Effectiveness and Adoption Challenges

While the FDA has approved the device based on clinical trial data, questions remain about its long-term effectiveness, durability, and how it will perform in diverse real-world settings. It is also unclear how healthcare providers will integrate this technology into standard care protocols, and whether insurance coverage will be widespread. Additionally, the device’s accuracy in various skin types and conditions is still being evaluated, and further studies are needed to confirm its benefits over existing monitoring methods.

Next Steps for Deployment and Further Research

Following FDA approval, the manufacturer plans to initiate broader commercial rollout, targeting adult users with diabetes at risk of ketoacidosis. Regulatory agencies and independent researchers will likely continue to monitor the device’s performance and safety in real-world use. Future studies may focus on pediatric populations, long-term health outcomes, and integration with other digital health tools. Healthcare providers will need to evaluate how best to incorporate the device into comprehensive diabetes management strategies.

Key Questions

How does the wearable monitor ketone and blood sugar levels?

The device uses biosensing technology embedded in a wristband to measure chemical markers through the skin surface, providing continuous data on ketone and glucose levels without the need for blood samples.

Can this device replace traditional blood tests?

No, the FDA states that KetoneSense is intended to support, not replace, standard blood testing and medical advice. It offers real-time monitoring but should be used alongside traditional methods and healthcare guidance.

Is the device suitable for children or adolescents?

Currently, the device is approved only for adult use. Further research and regulatory review are needed before it can be recommended for pediatric populations.

When will the device be available to consumers?

The manufacturer plans to begin commercial distribution within the next few months, pending final regulatory and supply chain arrangements.

What are the potential benefits of dual monitoring?

Real-time data on both ketone and blood sugar levels can enable earlier detection of dangerous conditions like ketoacidosis, potentially reducing hospitalizations and improving disease management.

Source: hn